Drugfacts-Marijuana.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning
6 Clearing the Smoke on Cannabis Regular Use and Cognitive Functioning Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Amy Porath, Ph.D., Director, Research, CCSA Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more This is the first in a series of reports noticeable cognitive impairment. that reviews the effects of cannabis • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest use on various aspects of human predictors of cognitive impairment. However, it is unclear which comes functioning and development. This first — whether cognitive impairment leads to early onset cannabis use or report on the effects of chronic whether beginning cannabis use early in life causes a progressive decline in cannabis use on cognitive functioning cognitive abilities. provides an update of a previous report • Regular cannabis use is associated with altered brain structure and function. with new research findings that validate Once again, it is currently unclear whether chronic cannabis exposure and extend our current understanding directly leads to brain changes or whether differences in brain structure of this issue. Other reports in this precede the onset of chronic cannabis use. series address the link between chronic • Individuals with reduced executive function and maladaptive (risky and cannabis use and mental health, the impulsive) decision making are more likely to develop problematic cannabis use and cannabis use disorder. -
Cannabis – a Complex and Rapidly Evolving Landscape
CANNABIS – A COMPLEX AND RAPIDLY EVOLVING LANDSCAPE Abstract ABOUT THE AUTHOR The humble Cannabis sativa plant, cultivated for millennia for its psychoactive properties and more, is today considered one of the most controversial and complex plants in the world. Starting in the early to mid-20th century, much of its use became recreational, but by the early 1970s discoveries began to emerge around its potential medical efficacies. This article will discuss current knowledge of how cannabis engages with the brain and the endocannabinoid system (ECS) and provide an overview of the new market landscapes brought about by changes in governing laws Dr. Georgiana Willwerth-Pascutiu and regulations, which are affecting usage by our current and potential [email protected] customers. It will also explore the additional hazards, concerns, and Georgiana Willwerth-Pascutiu is Vice President, Global Medical Director considerations of cannabis use in countries where it remains illegal. at RGA. She is board certified in Insurance Medicine by the American Introduction Academy of Insurance Medicine (AAIM) and specialized in internal medicine, Naturally occurring psychoactive substances have been part of human life nephrology and ultrasonography. for millennia. One of the most frequently utilized plant sources of these Dr. Willwerth-Pascutiu is also a past substances, Cannabis sativa, is also the best-known worldwide. For the president of the Canadian Life Insurance Medical Officers Association (CLIMOA) past half-century, scientific and medical interest in its many compounds, and currently chairs its scientific known as cannabinoids, has been increasing. Today, the two best-known, committee. She is a frequent presenter and has contributed several articles to delta-9 tetrahydrocannabinol (THC), its psychoactive chemical, and insurance industry publications. -
Medical Cannabis Q&A
Medical Cannabis Q&A 1. What is medical cannabis? The term “medical cannabis” is used to describe products derived from the whole cannabis plant or its extracts containing a variety of active cannabinoids and terpenes, which patients take for medical reasons, after interacting with and obtaining authorization from their health care practitioner. 2. What are the main active ingredients? The chemical ingredients of cannabis are called cannabinoids. The two main therapeutic ones are: THC:CBD a. Tetrahydrocannabinol (THC) is a partial agonist of CB1 and CB2 receptors. It is psychoactive and produces the euphoric effect. Each cannabis product will contain THC and CBD, however b. Cannabidiol (CBD) has a weak affinity for CB1 and CB2 receptors and appears the THC: CBD ratio will differ to exert its activity by enhancing the positive effects of the body’s endogenous depending on the product. cannabinoids. 3. Why do patients take it? Medical cannabis may be used to alleviate symptoms for a variety of conditions. It has most commonly been used in neuropathic pain and other chronic pain conditions. There is limited, but developing clinical evidence surrounding its safety and efficacy, and it does not currently have an approved Health Canada indication. 4. How do patients take it? Cannabis can be smoked, vaporized, taken orally, sublingually, topically or rectally. Different routes of administration will result in different pharmacokinetic and pharmacodynamic properties of the drug. 5. Is it possible to develop dependence on medical cannabis? Yes, abrupt discontinuation after long-term use may result in withdrawal symptoms. Additionally, chronic use may result in psychological dependence. -
A Review on Cannabis Sativa: Its Compounds and Their Effects
Int. J. Pharm. Sci. Rev. Res., 53(2), November - December 2018; Article No. 12, Pages: 59-63 ISSN 0976 – 044X Review Article A Review on Cannabis sativa: Its Compounds and Their Effects Ranju Rajput, *Dr. Krishan Kumar Department of Food and Biotechnology, Jayoti Vidyapeeth Women’s University, Jaipur, Rajasthan, India. *Corresponding author’s E-mail: [email protected] Received: 01-11-2018; Revised: 25-11-2018; Accepted: 10-12-2018. ABSTRACT Our society often considered the use of cannabis is an under-reported activity. Cannabis is used to relieve neuropathic and chronic pain. Cannabis, produced from the Cannabis sativa plant, have been used in three forms: herbal cannabis, the dried leaves and flowering tops The resin of the cannabis is the pressed secretions of the plant, known as ‘hashish’ or ‘charash. Cannabis sativa is an herbaceous species originated from Central Asia. It has been used in medicine and as a source of textile fiber since ancient times. The cannabis sativa is a fast growing plant attracted the people’s interest because of its multi-purpose applications. It is a rich source of photochemical, cellulose and woody fibers. The more interest is also due to its metabolites which show potent bioactivities on human health. In this review, the phytochemicals is discussed by putting a special emphasis on molecules including cannabinoids, terpenes and phenolic compounds. Cannabinoids are represented as the most studied group of compounds, because of their wide range of pharmaceutical effects in humans, including psychotropic activities. This article aims to update the current knowledge and evidence of using cannabis and its derivatives with a view to the sociolegal context and perspectives for future research. -
15.04.610.270 - Marijuana/Cannabis Commercial Uses
15.04.610.270 - Marijuana/Cannabis Commercial Uses. Commercial Cannabis activities, including but not limited to cultivation, manufacturing, testing, distribution, and retail are subject to the standards and procedures of the Municipal Code, State Law, and the regulations set forth in these Zoning Regulations. A. Applicability. These standards apply to all establishments that are involved in any commercial cannabis activity. B. Definitions1 []. The following words or phrases, whenever used in this section, have the following definitions: 1. A-license. A State license issued for cannabis or cannabis products that are intended for adults 21 years of age and over and who do not possess physician's recommendations. 2. Attending Physician. An individual who possesses a license in good standing to practice medicine or osteopathy issued by the Medical Board of California or the Osteopathic Medical Board of California and who has taken responsibility for an aspect of the medical care, treatment, diagnosis, counseling, or referral of a patient and who has conducted a medical examination of that patient before recording in the patient's medical record the physician's assessment of whether the patient has a serious medical condition and whether the medical use of cannabis is appropriate. 3. Bureau of Cannabis Control ("the Bureau"). The bureau within the California Department of Consumer Affairs created to develop, administer and enforce comprehensive rules for medicinal and adult-use cannabis in California. The Bureau is responsible for the regulation and licensing of all commercial cannabis retail, distribution, testing, microbusinesses and temporary cannabis events in California. 4. California Department of Food and Agriculture — CalCannabis Cultivation Licensing ("the CDFA"). -
Should Per Se Limits Be Imposed for Cannabis? Equating Cannabinoid Blood Concentrations with Actual Driver Impairment: Practical Limitations and Concerns
HUMBOLDT JOURNAL OF SOCIAL RELATIONS—ISSUE 35, 2013 Should Per Se Limits Be Imposed For Cannabis? Equating Cannabinoid Blood Concentrations with Actual Driver Impairment: Practical Limitations and Concerns Paul Armentano National Organization for the Reform of Marijuana Laws [email protected] ________________________________________________________________________ Abstract Fourteen US states have amended their longstanding, effect-based DUI drug laws to per se or zero tolerant per se statutes in regard to cannabis. Other states are considering enacting similar legislation. Under these amended traffic safety laws, it is a criminal violation for one to operate a motor vehicle with trace levels of cannabinoids or their metabolites in his or her blood or urine. Opponents of per se cannabinoid limits argue that neither the presence of cannabinoids nor their metabolites are appropriate or consistent predictors of behavioral or psychomotor impairment. They further argue that the imposition of such per se limits may result in the criminal conviction of individuals who may have previously consumed cannabis at some unspecified point in time, but were no longer under its influence. As more states enact statutory changes allowing for the legal use of cannabis under certain circumstances, there is a growing need to re-examine the appropriateness of these proposed per se standards for cannabinoids and their metabolites because the imposition of such limits may, in some instances, inadvertently criminalize behavior that poses no threat to traffic safety, -
Bill Analysis and Fiscal Impact Statement
The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional Staff of the Committee on Agriculture BILL: SB 1766 INTRODUCER: Senator Powell SUBJECT: Sale of Hemp-derived Delta-8-tetrahydrocannabinol DATE: March 16, 2021 REVISED: ANALYST STAFF DIRECTOR REFERENCE ACTION 1. Becker Becker AG Pre-meeting 2. CJ 3. RC I. Summary: SB 1788 creates s. 581.218, F.S., to regulate the sale of hemp-derived delta-8- tetrahydrocannabinol (delta-8-THC) products. It provides definitions for certain terms relating to the sale of delta-8-THC products. The bill specifies that a sale of hemp-derived dela-8-THC products constitutes a delivery sale regardless of whether the person accepting the order for the delivery is located in Florida. A retailer who mails or ships any hemp-derived delta-8-THC products must: Obtain a certification from the consumer who is purchasing the product that he or she is 21 years of age or older; Include as part of the order’s shipping documents, in a clear and conspicuous manner, the following statement: “Hemp-derived Delta-8-Tetrahydrocannabinol Products: Florida law prohibits shipping to individuals under 21 years of age and requires the payment of all applicable taxes”; and Be in compliance with any labeling requirements, pursuant to Department of Agriculture and Consumer Services rule for the state hemp program. The bill outlines specific violations that are misdemeanors of the first degree. The bill is effective July 1, 2021 BILL: SB 1766 Page 2 II. -
Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions. -
Marinol Cannabidiol C21H30O2 Trade Name
Cannabinoids are a group of terpenophenolic compounds secreted by Cannabis flowers that provide relief from a wide array of symptoms including, pain, nausea, and inflammation. They operate by imitating the body’s natural endocannabinoids, which activate to maintain internal stability and overall health. When consumed, cannabinoids bind to receptor sites throughout the brain (CB1 receptors) and body (CB2 receptors). Different cannabinoids have different effects based on their binding affinity for each receptor. By targeting specific cannabinoids at these receptors, different types of relief can be achieved. Presently, there are at least 113 different cannabinoids isolated from Cannabis—each exhibiting varied effects. THC Tetrahydrocannabinol C21H30O2 Trade name: Marinol Legal Status: US – Schedule I, Schedule II (as Cesamet), Schedule III (as Marinol) OH CA – Schedule II UK – Class B AU – S8 (controlled) H Psychoactive Tetrahydrocannabinol (THC) is typically the most abundant cannabinoid present in cannabis products on the market today. THC has very high psychoactive characteristics and is associated with the ‘high’ and euphoria experienced when using cannabis products. When smoked or ingested, THC binds to cannabinoid receptors throughout the body and affects memory, O coordination, concentration, pleasure, and time perception. H Medicinal Benefits Analgesic • Anti-nauseant • Appetite Stimulant Reduces Glaucoma Symptoms Sleep Aid • Reduces Anxiety and PTSD Symptoms CBD Cannabidiol C21H30O2 Trade name: Epidiolex OH Legal Status: US – Schedule I CA – Schedule II UK – POM (Perscription only) H AU – S4 (Perscription only) non-psychoactive Cannabidiol (CBD) is a major phytocannabinoid and accounts for up to 40% of the plant’s extract. Due to its lack of psychoactivity and HO non-interference with motor and psychological functions, it is a leading candidate for a wide variety of medical applications. -
Identfication: Industrial Hemp O Marijuana?
Identification: Industrial Hemp branching. Thus, planting density and other production or Marijuana? characteristics do not offer a reliable way to distinguish varieties for law enforcement purposes. Marijuana and industrial hemp are different varieties of the same plant species, Cannabis sativa L. Health Canada announced regulations on March 12, Marijuana typically contains 3 to 15 percent THC on a 1998, that control activities relating to the production, dry-weight basis, while industrial hemp contains less import, export, transport, and sale of industrial hemp than 1 percent (Blade, 1998; Vantreese, 1998). Most (see Appendix I for the fact sheet from Health developed countries that permit hemp cultivation Canada). Production is highly regulated, with farmers require use of varieties with less than 0.3 percent required to obtain annual government permits. Farmers THC. However, the two varieties are indistinguishable cannot have had a drug offense in the past 10 years by appearance. DeMeijer et al. (1992), in a study of 97 and need to have a criminal background check done at Cannabis strains, concluded that short of chemical their own expense. Federal agronomists and police analysis of the THC content, there was no way to dis- will check fields and test plants to make sure that no tinguish between marijuana and hemp varieties. narcotic plants are grown along with the industrial hemp. Industrial hemp can be grown as a fiber and/or seed crop. Grown for fiber, it is planted in dense stands to The European Union (EU) issued rules governing maximize stalk production. Grown for seed or for seed hemp production in 1989, which include registration and fiber, plants are spaced farther apart to encourage of the area to be planted in advance, the use of seed branching and seed production. -
Synthetic Cannabis
Global emergence of synthetic cannabinoids Source: https://www.unodc.org/LSS/SubstanceGroup/Details/ae45ce06-6d33-4f5f-916a- e873f07bde02 Source: UNODC questionnaire on NPS, 2012 Background The appearance of ‘herbal highs’ in the market is not a new phenomenon. Such products usually consisted of plant mixtures with little psychoactive effects. Since 2004, however, the composition of these herbal products seems to have substantially changed to include potent new psychoactive compounds known as synthetic cannabinoids. Research on the mechanism of cannabis activity dates back several decades when molecules with similar behaviour to Δ9-tetrahydrocannabinol (THC) were first examined. A synthetic analogue of THC , ‘HU-210’, was first synthesized in Israel in 1988[1]and is considered to have a potency of at least 100 times more than THC. Due to its similar chemical structure to THC, ‘HU-210’ is regarded as a ‘classical cannabinoid’ and has been found in synthetic cannabinoids sold in the United States and other countries. Non-classical cannabinoids include cyclohexylphenols or 3-arylcyclohexanols (‘CP’compounds). ‘CP’ compounds were developed as potential analgesics by a pharmaceutical company in the 1980s. Respondents to the UNODC questionnaire on NPS have reported the emergence of CP-47,497 and CP-47,497-C8 in numerous countries in all regions except Africa since 2009. Other structurally dissimilar varieties of synthetic cannabinoids unrelated to THC have also emerged on the market. These include aminoalkylindoles, such as naphthoylindoles (e.g. JWH-018), phenylacetylindoles (e.g. JWH-250), and benzoylindoles (e.g. AM-2233).[2] JWH-018, arguably the most widely known synthetic cannabinoid, belongs to the group of aminoalkylindoles and is considered to be three times as potent as THC. -
'Ultralight' Weed 20 June 2018
High hopes: French shops use loophole to sell 'ultralight' weed 20 June 2018 Technically, the fragrant marijuana buds on offer at you don't get addicted," an elderly woman said while a new Paris boutique are not meant to be smoked, waiting in line—before the doorman escorted her as the friendly staff and disclaimers remind straight inside. clients—brewing the herb in hot water is advised, as is adding it to food. CBD oil had sold out earlier in the day, so most clients were choosing among three or four different "Smoking is bad for you," a smiling young strains of potent-smelling weed—the popular Swiss salesman tells a customer. Cheese was priced at 30 euros for a 2.3-gram bag ($35 for just under one-tenth of an ounce). But judging by the 45-minute wait to get inside the Cofyshop near the Republique square on a recent 'Smell that!' afternoon, not to mention the smoking paraphernalia behind the counter, that certainly Unlike the coffeeshops in marijuana-friendly seems to be the goal. Amsterdam, no coffee is served and no smoking is allowed at Cofyshop. France is one of Europe's biggest users of cannabis, with an estimated 22 percent of people Fans of its "ultralight" buds as well as cannabis aged 15 to 34 partaking at least once in 2016, resin say they appreciate the calming effects according to the latest data available. without the heavy buzz of traditional marijuana. A recent French poll showed 51 percent in favour "Smell that, it's fantastic!" said a 37-year-old dentist of limited legalisation, reflecting a growing trend at a boutique on the hip Rue Oberkampf in Paris, toward more relaxed rules in Europe and the who said he smokes a joint or two every now and United States.